Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × brolucizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1 Macular Degeneration 1

Interventions

Cyclophosphamide 801 Carboplatin 688 Paclitaxel 647 Bevacizumab 641 pembrolizumab 607 Cisplatin 606 Gemcitabine 540 Docetaxel 503 Rituximab 494 Radiotherapy 486 Dexamethasone 440 Nivolumab 415 Doxorubicin 392 Fluorouracil 342 Capecitabine 341 Etoposide 315 Oxaliplatin 294 Cytarabine 291 Prednisone 290 Pemetrexed 289 Lenalidomide 286 Erlotinib Hydrochloride 281 fludarabine phosphate 277 Leucovorin 266 fludarabine 261 Trastuzumab 259 Filgrastim 252 Vincristine 252 Bortezomib 249 Cetuximab 235

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡